Maxigen BiotechTPE:1783 +0.12%87 PEG Ratio is 0.66 as of Jul. 08, 2026, which is 47% below its 10-year median of 1.24. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.18 (Significantly Undervalued). Among 208 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 82.21% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Maxigen Biotech's PEG Ratio or its related term are showing as below:
TPE:1783'
s PEG Ratio Range Over the Past 10 Years
Min: 0.65 Med: 1.24 Max: 2.08
Current: 0.66
During the past 13 years, Maxigen Biotech's highest PEG Ratio was 2.08. The lowest was 0.65. And the median was 1.24.
TPE:1783's PEG Ratio is ranked better than 82.21% of 208
companies
in the Medical Devices & Instruments industry
Industry Median: 1.975
vs TPE:1783: 0.66
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Maxigen Biotech (TPE:1783) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Maxigen Biotech PEG Ratio Related Terms
Maxigen Biotech PEG Ratio Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech PEG Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Maxigen Biotech (TPE:1783) has a PEG Ratio of 0.66 as of Jul. 08, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Maxigen Biotech and its competitors. This is 47% below median its historical median of 1.24. Over the past decade, Maxigen Biotech's PEG Ratio has ranged from 0.65 to 2.08. According to the industry distribution chart, Maxigen Biotech ranks #37 out of 208 companies in the Medical Devices & Instruments industry, placing it in the top 17.8%.
Is Maxigen Biotech's PEG Ratio too high?
Maxigen Biotech's current PEG Ratio of 0.66 is 47% below median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 2.08. The Medical Devices & Instruments industry median PEG Ratio is 1.98. Maxigen Biotech's value of 0.66 is 66.6% below this industry median. Based on the distribution chart, Maxigen Biotech ranks #37 out of 208 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's PEG Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #37 out of 208 companies for PEG Ratio. This places Maxigen Biotech in the top 18% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.98. Maxigen Biotech's value of 0.66 is 66.6% below this benchmark. Historically, Maxigen Biotech's own PEG Ratio has ranged from 0.65 to 2.08 over the past decade. While the company's 10-year median is 1.24 vs. the industry median of 1.98, Maxigen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 1.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current PEG Ratio of 0.66 is 66.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current PEG Ratio is 0.66, which is 47% below median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.18, compared to a current price of NT$40.65 — trading 33.6% below its estimated fair value. The current PEG Ratio is 0.66, which is 47% below median its 10-year median of 1.24 and 66.6% below the Medical Devices & Instruments industry median of 1.98. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current PEG Ratio is 0.66 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$40.65 is trading 33.6% below its estimated GF Value™ of NT$61.18.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
PEG Ratio: 0.66 (47% below median its 10-year median of 1.24)
GF Value™: NT$61.18 vs. price of NT$40.65 (33.6% below fair value)
Industry Position: 66.6% below the Medical Devices & Instruments median (#37 of 208)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
